AbbVie and EvolveImmune Therapeutics, an immuno-oncology company developing next-gen biotherapeutics, entered a collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology. The discovery partnership will leverage EvolveImmune’s T-cell engager platform to develop novel antibody-based therapies for solid and hematologic malignancies.   EvolveImmune will receive $65 million upfront and an equity investment from AbbVie and is eligible for...